SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016)
SELLAS Life Sciences (SLS) reported Convertible Debt of $5.7 million for Q4 2016, up 465.9% quarter-over-quarter from $1.0 million in Q1 2012.
SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016) Analysis & Trends
SELLAS Life Sciences (SLS) has 2 years of Convertible Debt data on file, last reported at $5.7 million in Q4 2016.
- Convertible Debt for Q4 2016 came in at $5.7 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $5.7 million (changed N/A YoY), and the FY2016 annual result was $5.7 million, changed N/A from the prior year.
- Convertible Debt advanced to $5.7 million in Q4 2016 per SLS's latest filing, from $1.0 million in the prior quarter.
- Over five years, Convertible Debt peaked at $5.7 million in Q4 2016 and troughed at $1.0 million in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 5.66 Mn |
| Mar 31, 2012 | 1.00 Mn |